Uterine cancer is now considered the deadliest cancer affecting the female reproductive system.
Every year, tens of thousands of women are diagnosed with the disease, and many die when treatments stop working.
Doctors usually rely on surgery and chemotherapy to treat uterine cancer, especially in the early stages.
These treatments can help many patients survive, but not everyone responds well. For women whose cancer returns or continues growing after treatment, the options become very limited.
Now, researchers from the Yale School of Medicine may have found a new way to help patients with treatment-resistant uterine cancer.
Their study suggests that a drug already used for advanced breast cancer may also work against difficult uterine tumors. The findings were published on May 14 in the medical journal Clinical Cancer Research.
The drug is called sacituzumab govitecan. It is a newer type of chemotherapy known as targeted chemotherapy. Unlike standard chemotherapy, which attacks many healthy cells along with cancer cells, targeted chemotherapy is designed to focus more directly on tumor cells. This may reduce some of the harmful side effects often linked to cancer treatment.
Researchers found that the drug helped shrink tumors in 28% of patients with treatment-resistant uterine cancer. This makes it one of the most successful third-line treatments currently studied for the disease. Third-line treatment means it is used after the first and second treatment options have already failed.
The lead researcher, Dr. Alessandro Santin from Yale School of Medicine and Yale Cancer Center, said this group of patients desperately needs better treatment choices. According to Santin, many women with advanced uterine cancer are left with almost no options once surgery and regular chemotherapy stop working.
Uterine cancer affects the lining of the uterus and is sometimes called endometrial cancer. Around 3% of women will develop uterine cancer during their lives. The National Institutes of Health estimates that nearly 68,000 Americans will be diagnosed with the disease in 2026 alone.
Although many patients survive when the cancer is caught early, thousands still die each year. Experts believe the number of uterine cancer cases may double by 2030. One reason is that there is no standard screening test for uterine cancer like there is for breast or colon cancer.
Researchers have spent years searching for safer and more effective treatments. More than ten years ago, Santin and his team identified a protein called Trop-2 that appears in high amounts on uterine cancer cells. This discovery opened the possibility of designing a treatment that specifically targets these cancer cells.
Sacituzumab govitecan works by using an antibody to find and attach to Trop-2 proteins on cancer cells. Once attached, the drug delivers chemotherapy directly into the tumor. This approach helps concentrate the treatment where it is needed most while reducing damage to healthy tissues.
The drug was developed through collaboration between Yale researchers and the pharmaceutical company Immunomedics, which later became part of Gilead Sciences. In 2023, the U.S. Food and Drug Administration approved the drug for certain forms of advanced breast cancer after studies showed encouraging results.
The new study wanted to find out whether the same treatment could help uterine cancer patients whose disease no longer responded to standard therapies.
The researchers enrolled 50 patients with advanced uterine cancer. All had previously undergone surgery and chemotherapy without success. Patients received two doses of sacituzumab govitecan every 21 days.
After several treatment cycles, doctors measured how the tumors responded. Fourteen patients experienced tumor shrinkage of at least 30%. Overall, more than 70% of patients saw some degree of tumor reduction.
These results are important because most chemotherapy treatments used at this late stage only help a small percentage of patients. In many cases, fewer than 15% respond to existing drugs.
The treatment did cause side effects. Some patients developed low white blood cell counts, diarrhea, and bone marrow problems. However, the researchers reported that these side effects were manageable with supportive medical care and were generally less severe than those seen with standard chemotherapy.
The promising findings have already led to plans for a larger Phase III clinical trial. This next study will compare sacituzumab govitecan directly against standard chemotherapy in a bigger group of uterine cancer patients.
Researchers believe the study also reflects a much larger change happening in cancer care. For many years, cancer treatment followed a “one-size-fits-all” approach where patients often received the same chemotherapy drugs regardless of their tumor biology.
Now, scientists are moving toward more personalized medicine. Treatments are increasingly being designed to target specific proteins or genetic changes inside cancer cells. Experts believe this strategy may improve results while reducing harmful side effects.
Dr. Santin believes drugs like sacituzumab govitecan represent the future of cancer treatment. Instead of attacking the whole body, these therapies aim to strike cancer more precisely.
The study still has limitations. The trial involved only 50 patients, and larger studies are needed before the treatment becomes a standard option for uterine cancer. Researchers also need to understand which patients are most likely to benefit.
Still, the findings offer real hope to women facing advanced uterine cancer with few remaining choices. If future trials confirm the results, this breast cancer drug could become an important new weapon against one of the deadliest cancers affecting women.
Reviewing the findings, the study appears highly promising because the drug showed much stronger results than many current late-stage treatments. The ability to directly target cancer cells through the Trop-2 protein may explain why the treatment worked better than standard chemotherapy in some patients.
However, because the trial was relatively small, scientists must still confirm long-term safety and effectiveness in larger patient groups. Even so, the research highlights how targeted therapies may transform cancer care in the coming decades by offering more personalized and less toxic treatments for difficult cancers.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
